Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
- Published In:
- Lancet (London, England), 358(9288), 1119-23 (2001)
- Authors:
- Channick, R N, Simonneau, G, Sitbon, O, Robbins, I M, Frost, A, Tapson, V F, Badesch, D B, Roux, S, Rainisio, M, Bodin, F, Rubin, L J
- Database ID:
- RPEP-00657
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00657APA
Channick, R N; Simonneau, G; Sitbon, O; Robbins, I M; Frost, A; Tapson, V F; Badesch, D B; Roux, S; Rainisio, M; Bodin, F; Rubin, L J. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.. Lancet (London, England), 358(9288), 1119-23.
MLA
Channick, R N, et al. "Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.." Lancet (London, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Effects of the dual endothelin-receptor antagonist bosentan ..." RPEP-00657. Retrieved from https://rethinkpeptides.com/research/channick-2001-effects-of-the-dual
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.